25-Methoxyhispidol A, a novel triterpenoid of Poncirus trifoliata, inhibits cell growth via the modulation of EGFR/c-Src signaling pathway in MDA-MB-231 human breast cancer cells

Food and Chemical Toxicology

Volumn 49, Issue 11, 2011, Pages 2942-2946

  Chung, Hwa Jin ^a   Park, Eun Jung ^b   Pyee, Yuna ^a   Hua Xu, Guang ^c   Lee, Seung Ho ^c   Kim, Young Shik ^a   Lee, Sang Kook ^a  

^a Seoul National University   (South Korea)

^b Ewha Womans University   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

25 Methoxyhispidol A; C Src; Cell cycle arrest; EGFR; MDA MB 231; Poncirus trifoliata

Indexed keywords

25 METHOXYHISPIDOL A; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE P60; RETINOBLASTOMA PROTEIN; S6 KINASE; TRITERPENOID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL STRAIN; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOMODULATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRIFOLIATE ORANGE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR STRUCTURE; PONCIRUS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRITERPENES;

PONCIRUS TRIFOLIATA; RUTACEAE;

EID: 81155162569     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.07.001     Document Type: Article

References (19)

1. Bagatell R., Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 2004, 3:1021-1030.
2. Biscardi J.S., Belsches A.P., Parsons S.J. Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol. Carcinog. 1998, 21:261-272.
3. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2000, 2:203-210.
4. Chavez I.O., Apan T.R., Martinez-Vazquez M. Cytotoxic activity and effect on nitric oxide production of tirucallane-type triterpenes. J. Pharm. Pharmacol. 2005, 57:1087-1092.
5. Chen G., Lu H., Wang C., Yamashita K., Manabe M., Xu S., Kodama H. Effect of five triterpenoid compounds isolated from leaves of Diospyros kaki on stimulus-induced superoxide generation and tyrosyl phosphorylation in human polymorphonuclear leukocytes. Clin. Chim. Acta 2002, 320:11-16.
6. Dzubak P., Hajduch M., Vydra D., Hustova A., Kvasnica M., Biedermann D., Markova L., Urban M., Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat. Prod. Rep. 2006, 23:394-411.
7. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/Akt pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
8. Hong J.Y., Min H.Y., Xu G.H., Lee J.G., Lee S.H., Kim Y.S., Kang S.S., Lee S.K. Growth inhibition of G1 cell cycle arrest mediated by 25-methoxyhispidol A, a novel triterpenoid, isolated from the fruit of Poncirus trifoliata in human hepatocellular carcinoma cells. Planta Med. 2008, 74:151-155.
9. Kopelovich L., Fay J.R., Sigman C.C., Crowell J.A. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidermiol. Biomark. Prev. 2007, 16:1330-1340.
10. Lee S.K., Heo Y.H., Steele V.E., Pezzuto J.M. Induction of apoptosis by 1,4-phenylenebis(methylene)selenocyanate in cultured human colon cancer cells. Anticancer Res. 2002, 22:97-102.
11. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer 2001, 37:S9-S15. (S45-S50).
12. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 2006, 24:1770-1783.
13. Sheikh M.S., Garcia M., Pujol P., Fontana J.A., Rochefort H. Why are estrogen-receptor-negative breast cancers more aggressive than the estrogen-receptor-positive breast cancers?. Invas. Metastat. 1994, 14:329-336.
14. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
15. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.T., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150:76-85.
16. Tolaney S.M., Winer E.P. Follow-up care of patients with breast cancer. Breast 2007, 2:S45-S50.
17. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
18. Xu G.H., Kim J.A., Kim S.Y., Ryu J.C., Kim Y.S., Jung S.H., Kim M.K., Lee S.H. Terpenoids and coumarins isolated from the fruits of Poncirus trifoliata. Chem. Pharm. Bull. 2008, 56:839-842.
19. Zandi R., Larsen A.B., Andersen P., Stockhausen M.T., Poulsen H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal. 2007, 19:2013-2023.